232 related articles for article (PubMed ID: 36653879)
1. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
Lalu MM; Kekre N; Montroy J; Ghiasi M; Hay K; McComb S; Weeratna R; Atkins H; Hutton B; Yahya A; Masurekar A; Sobh M; Fergusson DA
Syst Rev; 2023 Jan; 12(1):9. PubMed ID: 36653879
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
5. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
6. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews.
Khan ST; Montroy J; Forbes N; Bastin D; Kennedy MA; Diallo JS; Kekre N; Fergusson DA; Lalu M; Auer RC
BMJ Open; 2020 Jun; 10(6):e034714. PubMed ID: 32518209
[TBL] [Abstract][Full Text] [Related]
8. CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM; Latorraca CDOC; Pacheco RL; Riera R
Eur J Haematol; 2022 Dec; 109(6):601-618. PubMed ID: 36018500
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
10. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
11. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
[TBL] [Abstract][Full Text] [Related]
12. Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery.
Lam C; Meinert E; Halioua-Haubold CL; Carter A; Yang A; Brindley D; Cui Z
BMJ Open; 2019 Jul; 9(7):e026172. PubMed ID: 31278092
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Protocol for individual participant data meta-analysis of randomised controlled trials of patients with psychosis to investigate treatment effect modifiers for CBT versus treatment as usual or other psychosocial interventions.
Sudell M; Tudur-Smith C; Liao X; Longden E; Dunn G; Kendall T; Emsley R; Morrison A; Varese F
BMJ Open; 2021 May; 11(5):e035062. PubMed ID: 34049898
[TBL] [Abstract][Full Text] [Related]
16. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
19. Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.
Zhang G; Deng L; Lu H; Zhang W
Int J Clin Pharm; 2024 Feb; 46(1):186-194. PubMed ID: 38087131
[TBL] [Abstract][Full Text] [Related]
20. EstablishINg the best STEp-up treatments for children with uncontrolled asthma despite INhaled corticosteroids (EINSTEIN): protocol for a systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data (IPD).
Cividini S; Sinha I; Donegan S; Maden M; Culeddu G; Rose K; Fulton O; Hughes DA; Turner S; Tudur Smith C
BMJ Open; 2021 Feb; 11(2):e040528. PubMed ID: 33550231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
